Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Receivables (2018 - 2025)

Wave Life Sciences' Change in Receivables history spans 7 years, with the latest figure at -$8.7 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 713.5% year-over-year to -$8.7 million; the TTM value through Dec 2025 reached -$146000.0, up 99.26%, while the annual FY2025 figure was -$146000.0, 99.26% up from the prior year.
  • Change in Receivables reached -$8.7 million in Q4 2025 per WVE's latest filing, down from $8.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $14.1 million in Q4 2023 to a low of -$37.5 million in Q3 2021.
  • Average Change in Receivables over 4 years is -$4.9 million, with a median of $0.0 recorded in 2024.
  • The largest YoY upside for Change in Receivables was 749.84% in 2025 against a maximum downside of 713.5% in 2025.
  • A 4-year view of Change in Receivables shows it stood at -$22.5 million in 2021, then skyrocketed by 162.6% to $14.1 million in 2023, then tumbled by 89.9% to $1.4 million in 2024, then plummeted by 713.5% to -$8.7 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Change in Receivables are -$8.7 million (Q4 2025), $8.4 million (Q3 2025), and $1.6 million (Q2 2025).